Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Get all the latest ESC Pocket Guidelines, plus interactive tools (algorithms, calculators, charts, scores...) in your pocket.
Withdrawal of sitaxentan in the treatment of pulmonary arterial hypertension
1. Preamble 2. Introduction 3. Definitions and classifications 3.1 Definitions 3.2. Classifications 4. Epidemiology and genetics of pulmonary hypertension 4.1 Epidemiology and risk factors 4.2 Genetics 5. Pulmonary hypertension diagnosis 5.1 Diagnosis5.1.1 Clinical presentation 5.1.2 Electrocardiogram 5.1.3 Chest radiograph 5.1.4 Pulmonary function tests and arterial blood gases 5.1.5 Echocardiography 5.1.6 Ventilation/perfusion lung scan 5.1.7 High-resolution computed tomography, contrast enhanced computed tomography, and pulmonary angiography 5.1.8 Cardiac magnetic resonance imaging 5.1.9 Blood tests and immunology5.1.10 Abdominal ultrasound scan 5.1.11 Right heart catheterization and vasoreactivity 5.1.12 Genetic testing 5.2 Diagnostic algorithm 6. Pulmonary arterial hypertension (group 1) 6.1 Clinical characteristics 6.2 Evaluation of severity6.2.1 Clinical parameters, imaging and haemodynamics 6.2.2 Exercise capacity 6.2.3 Biochemical markers 6.2.4 Comprehensive prognostic evaluation and riskassessment 6.2.5 Definition of patient status6.2.6 Treatment goals and follow-up strategy 6.3 Therapy 6.3.1 General measures 6.3.2 Supportive therapy 6.3.3 Specific drug therapy6.3.4 Combination therapy 6.3.5 Drug interactions6.3.6 Balloon atrial septostomy 6.3.7 Advanced right ventricular failure 6.3.8 Transplantation 6.3.9 Treatment algorithm 6.3.10 Diagnosis and treatment of pulmonary arterial hypertension complications 6.3.11 End of life care and ethical issues7. Specific pulmonary (arterial) hypertension subsets 7.1 Paediatric pulmonary arterial hypertension7.1.1 Diagnosis 7.1.2 Therapy 7.2 Pulmonary arterial hypertension associated with adult congenital heart disease 7.2.1 Diagnosis7.2.2 Therapy7.3 Pulmonary arterial hypertension associated with connective tissue disease 7.3.1 Diagnosis 7.3.2 Therapy 7.4 Pulmonary arterial hypertension associated with portal hypertension 7.4.1 Diagnosis 7.4.2 Therapy7.5 Pulmonary arterial hypertension associated with human immunodeficiency virus infection 7.5.1 Diagnosis 7.5.2 Therapy 7.6 Pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis 7.6.1 Diagnosis 7.6.2 Therapy 8. Pulmonary hypertension due to left heart disease (group 2)8.1 Diagnosis 8.2 Therapy9. Pulmonary hypertension due to lung diseases and/or hypoxia (group 3) 9.1 Diagnosis 9.2 Therapy 10. Chronic thromboembolic pulmonary hypertension (group 4) 10.1 Diagnosis 10.2 Therapy 10.2.1 Surgical 10.2.2 Medical 10.2.3 Interventional 11. Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5) 12. Definition of a pulmonary hypertension referral centre 13. To do and not to do messages from the guidelines 14. Appendix 15. Web addenda 16. References
© 2017 European Society of Cardiology. All rights reserved